Novel MRI Biomarkers for Monitoring Disease Progression in ALS

Recruiting

• Conditions: Motor Neuron Disease; Amyotrophic Lateral Sclerosis

• Registration Number: NCT03362658
• Lead Sponsor: University of Alberta

Brief Summary

Routine MRI is normal in motor neuron diseases such as ALS. However, advanced MRI techniques can provide an objective measure of degeneration (a "biomarker") by examining brain structure, wiring, chemistry, and function. We will develop and evaluate novel MRI techniques that could improve our understanding of ALS and provide a means to diagnose it sooner and monitor its progression. Importantly, we expect these techniques to improve how new drugs are tested, which may lead to the more rapid discovery of a treatment for ALS.

Each participant will have 3 MRI scans over a period of 8 months, along with neurological and cognitive evaluations. Study visits will take 2 - 3 hours. MRI is a safe technique that does not involve radiation.

Detailed Description

Current clinical measures of disease burden have suboptimal sensitivity to disease progression in ALS. A biomarker would play an essential role in the evaluation of novel therapeutics, leading to the realization of effective treatments faster. Magnetic resonance imaging (MRI) holds promise as a non-invasive source of biomarkers in ALS. In this study data is collected from a national imaging platform (the Canadian ALS Neuroimaging Consortium \[CALSNIC\]) using standardized MRI and clinical protocols.

CALSNIC was founded with the objective to validate MRI biomarkers on a standardized multi-centre platform. CALSNIC is a multidisciplinary group of scientists at 7 centres across Canada. The first CALSNIC study entitled "MRI Biomarkers in ALS" (CALSNIC-1) is ongoing and slated to finish recruitment in 2017.

This study ("Novel MRI Biomarkers for Monitoring Disease Progression in ALS", CALSNIC-2) is a new project that will evaluate novel MRI biomarkers using advanced imaging acquisition and processing methods. The specific aims of CALSNIC-2 are 1) to establish a standardized MRI and clinical protocol across the 7 centres, and 2) to validate MRI measures with clinical measures of disease burden and progression.

It is anticipated that the project will lead to the discovery of MR-based biomarkers of cerebral degeneration that can be applied across different centres and hence, can assist with drug development. Secondly, this project will expand CALSNIC to include more centres and provide opportunities for collaborative and multidisciplinary translational research on a national scale.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2016-10
• Study First Submitted: 2017-10-18
• Study First Submitted QC: 2017-11-29
• Study First Posted: 2017-12-05
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-16
• Last Update Posted: 2024-02-20
• Primary Completion: 2024-12-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 700

Inclusion Criteria

• Patients with a suspected or confirmed diagnosis as described in Study Populations
• For those with a diagnosis of ALS, patients will be considered with an El Escorial classification of suspected, possible, probable, probable lab-supported, and definite ALS.
• Patients 18 years of age or older
• Healthy controls over the age of 40.
• Be able to lie in an MRI machine for approximately 60 minutes

Read More

Exclusion Criteria

• Subjects with psychiatric/CNS illnesses such as Major Depressive Disorder, Schizophrenia, and Bipolar disorder.
• Subjects with significant head injury or other neurological disease (stroke, brain tumour).
• Subjects ineligible for MRI investigation due to a pacemaker or other metallic foreign body.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in DTI indices (unitless).	8 months	This primary analysis will evaluate white matter integrity at baseline and specified follow up periods. Patients and controls scans will be compared.
Change in cortical thickness in millimetres.	8 months	This primary analysis will evaluate neuronal integrity at baseline and specified follow up periods. Patients and controls scans will be compared.

Trial Locations

Locations (9)

University of Calgary / Heritage Medical Research Clinic; 🇨🇦 Calgary, Alberta, Canada

University of Alberta; 🇨🇦 Edmonton, Alberta, Canada

University of British Columbia / GF Strong Rehab Centre; 🇨🇦 Vancouver, British Columbia, Canada

Western University / London Health Sciences Centre; 🇨🇦 London, Ontario, Canada

University of Toronto / Sunnybrook Health Sciences Centre; 🇨🇦 Toronto, Ontario, Canada

McGill University / Montreal Neurological Institute and Hospital; 🇨🇦 Montreal, Quebec, Canada

Laval University; 🇨🇦 Quebec City, Quebec, Canada

University of Miami; 🇺🇸 Miami, Florida, United States

University of Utah; 🇺🇸 Salt Lake City, Utah, United States